Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A

Nuclear Medicine and Biology

Volumn 42, Issue 2, 2015, Pages 146-154

  Harada, Akina ^a   Suzuki, Kazunori ^a   Miura, Shotaro ^a   Hasui, Tomoaki ^a   Kamiguchi, Naomi ^a   Ishii, Tsuyoshi ^a   Taniguchi, Takahiko ^a   Kuroita, Takanobu ^a   Takano, Akihiro ^b   Stepanov, Vladimir ^b   Halldin, Christer ^b   Kimura, Haruhide ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Autoradiography; C 11; PDE10A; PET; T 773

Indexed keywords

1 [2 FLUORO 4 (TETRAHYDRO 2H PYRAN 4 YL)PHENYL] 5 METHOXY 3 (1 PHENYL 1H PYRAZOL 5 YL)PYRIDAZIN 4(1H) ONE C 11; 1 [2 FLUORO 4 (TETRAHYDRO 2H PYRAN 4 YL)PHENYL] 5 METHOXY 3 (1 PHENYL 1H PYRAZOL 5 YL)PYRIDAZIN 4(1H) ONE H 3; 2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE; MESSENGER RNA; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; RADIOLIGAND; UNCLASSIFIED DRUG; CARBON; LIGAND; PDE10A PROTEIN, MOUSE; PHOSPHODIESTERASE INHIBITOR; PROTEIN BINDING; PYRAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE; T-773 COMPOUND;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN TISSUE; CAUDATE NUCLEUS; COMPETITIVE INHIBITION; CORPUS STRIATUM; COS 7 CELL LINE; DRUG ACCUMULATION; DRUG PENETRATION; DRUG SPECIFICITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IC50; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; RAT; RHESUS MONKEY; SF9 CELL LINE; ANIMAL; BINDING COMPETITION; BRAIN; CHEMISTRY; DEFICIENCY; DIAGNOSTIC USE; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENETICS; METABOLISM; SCINTISCANNING;

ANIMALS; AUTORADIOGRAPHY; BINDING, COMPETITIVE; BRAIN; CARBON RADIOISOTOPES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE KNOCKOUT TECHNIQUES; HUMANS; LIGANDS; MACACA MULATTA; MALE; MICE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PYRAZOLES; PYRIDAZINES; RATS;

EID: 84921323693     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.09.005     Document Type: Article

References (44)

1. Fujishige K., Kotera J., Michibata H., Yuasa K., Takebayashi S., Okumura K., et al. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 1999, 274:18438-18445.
2. Seeger T.F., Bartlett B., Coskran T.M., Culp J.S., James L.C., Krull D.L., et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res 2003, 985:113-126.
3. Coskran T.M., Morton D., Menniti F.S., Adamowicz W.O., Kleiman R.J., Ryan A.M., et al. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 2006, 54:1205-1213.
4. Graybiel A.M. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990, 13:244-254.
5. Graybiel A.M. The basal ganglia. Curr Biol 2000, 10:R509-R511.
6. Karam C.S., Ballon J.S., Bivens N.M., Freyberg Z., Girgis R.R., Lizardi-Ortiz J.E., et al. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol Sci 2010, 31:381-390.
7. Krebs M., Leopold K., Hinzpeter A., Schaefer M. Current schizophrenia drugs: efficacy and side effects. Expert Opin Pharmacother 2006, 7:1005-1016.
8. Siuciak J.A., Chapin D.S., Harms J.F., Lebel L.A., McCarthy S.A., Chambers L., et al. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 2006, 51:386-396.
9. Menniti F.S., Chappie T.A., Humphrey J.M., Schmidt C.J. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs 2007, 8:54-59.
10. Kehler J., Nielsen J. PDE10A inhibitors: novel therapeutic drugs for schizophrenia. Curr Pharm Des 2011, 17:137-150.
11. Rourke C., Starr K.R., Reavill C., Fenwick S., Deadman K., Jones D.N. Effects of the atypical antipsychotics olanzapine and risperidone on plasma prolactin levels in male rats: a comparison with clinical data. Psychopharmacology 2006, 184:107-114.
12. Giampà C., Patassini S., Borreca A., Laurenti D., Marullo F., Bernardi G., et al. Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease. Neurobiol Dis 2009, 34:450-456.
13. Giampà C., Laurenti D., Anzilotti S., Bernardi G., Menniti F.S., Fusco F.R. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One 2010, 5:e13417.
14. Kleiman R.J., Kimmel L.H., Bove S.E., Lanz T.A., Harms J.F., Romegialli A., et al. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease. J Pharmacol Exp Ther 2011, 336:64-76.
15. Frank R., Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003, 2:566-580.
16. Halldin C., Gulyás B., Farde L. PET studies with carbon-11 radioligands in neuropsychopharmacological drug development. Curr Pharm Des 2001, 7:1907-1929.
17. Lee C.M., Farde L. Using positron emission tomography to facilitate CNS drug development. Trends Pharmacol Sci 2006, 27:310-316.
18. Celen S., Koole M., De Angelis M., Sannen I., Chitneni S.K., Alcazar J., et al. Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain. J Nucl Med 2010, 51:1584-1591.
19. Tu Z., Fan J., Li S., Jones L.A., Cui J., Padakanti P.K., et al. Radiosynthesis and in vivo evaluation of [11C]MP-10 as a PET probe for imaging PDE10A in rodent and non-human primate brain. Bioorg Med Chem 2011, 19:1666-1673.
20. Plisson C., Salinas C., Weinzimmer D., Labaree D., Lin S.F., Ding Y.S., et al. Radiosynthesis and in vivo evaluation of [(11)C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A. Nucl Med Biol 2011, 38:875-884.
21. Andrés J.I., De Angelis M., Alcázar J., Iturrino L., Langlois X., Dedeurwaerdere S., et al. Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging. J Med Chem 2011, 54:5820-5835.
22. Van Laere K., Ahmad R.U., Hudyana H., Celen S., Dubois K., Schmidt M.E., et al. Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging. Eur J Nucl Med Mol Imaging 2013, 40:254-261.
23. Celen S., Koole M., Ooms M., De Angelis M., Sannen I., Cornelis J., et al. Preclinical evaluation of [(18)F]JNJ42259152 as a PET tracer for PDE10A. NeuroImage 2013, 82:13-22.
24. Van Laere K., Ahmad R.U., Hudyana H., Dubois K., Schmidt M.E., Celen S., et al. Quantification of 18F-JNJ-42259152, a novel phosphodiesterase 10A PET tracer: kinetic modeling and test-retest study in human brain. J Nucl Med 2013, 54:1285-1293.
25. Hwang D.R., Hu E., Rumfelt S., Easwaramoorthy B., Castrillon J., Davis C., et al. Initial characterization of a PDE10A selective positron emission tomography tracer [11C]AMG 7980 in non-human primates. Nucl Med Biol 2014, 41:343-349.
26. Plisson C., Weinzimmer D., Jakobsen S., Natesan S., Salinas C., Lin S.F., et al. Phosphodiesterase 10A PET radioligand development program: from pig to human. J Nucl Med 2014, 55:595-601.
27. Fan J., Zhang X., Li J., Jin H., Padakanti P.K., Jones L.A., et al. Radiosyntheses and in vivo evaluation of carbon-11 PET tracers for PDE10A in the brain of rodent and nonhuman primate. Bioorg Med Chem 2014, 22:2648-2654.
28. Barret O., Thomae D., Tavares A., Alagille D., Papin C., Waterhouse R., et al. In vivo assessment and dosimetry of 2 novel PDE10A PET radiotracers in humans: 18F-MNI-659 and 18F-MNI-654. J Nucl Med 2014, 55:1297-1304.
29. Verhoest P.R., Chapin D.S., Corman M., Fonseca K., Harms J.F., Hou X., et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem 2009, 52:5188-5196.
30. Andersson J., Truong P., Halldin C. In-target produced [11C]methane: increased specific radioactivity. Appl Radiat Isot 2009, 67:106-110.
31. Stepanov V., Miura S., Takano A., Kimura H., Taniguchi T., Halldin C. Development of a series of novel carbon-11 labeled PDE10A inhibitors. J Labelled Comp Radiopharm 2013, S312. [Korea].
32. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, San Diego. 4th ed.
33. Paxinos G., Franklin K.B.J. The mouse brain in stereotaxic coordinates 2001, Academic Press, San Diego. 2nd ed.
34. Karlsson P., Farde L., Halldin C., Swahn C.G., Sedvall G., Foged C., et al. PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor. Psychopharmacology 1993, 113:149-156.
35. Waarde A. Measuring receptor occupancy with PET. Curr Pharm Des 2000, 6:1593-1610.
36. Bender A.T., Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006, 58:488-520.
37. Takano A. The application of PET technique for the development and evaluation of novel antipsychotics. Curr Pharm Des 2010, 16:371-377.
38. Farde L., Wiesel F.A., Halldin C., Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988, 45:71-76.
39. Nord M., Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci Ther 2011, 17:97-103.
40. Minuzzi L., Cumming P. Agonist binding fraction of dopamine D2/3 receptors in rat brain: a quantitative autoradiographic study. Neurochem Int 2010, 56:747-752.
41. Arakawa R., Ito H., Takano A., Okumura M., Takahashi H., Takano H., et al. Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects. Psychopharmacology 2010, 209:285-290.
42. Pike V.W. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci 2009, 30:431-440.
43. Raub T.J. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharm 2006, 3:3-25.
44. Waterhouse R.N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 2003, 5:376-389.